Healthcare major AbbVie has reported strong revenue growth in 2025, driven by double-digit gains in its immunology and neuroscience portfolios, even as earnings slipped modestly amid acquisition-related expenses.
For the full year, the drugmaker generated net revenues of $61.16 billion, up 8.6 percent on a reported basis and 8.5 percent operationally. GAAP diluted earnings per share came in at $2.36, down 1.3 percent from the prior year, while adjusted diluted EPS totaled $10.00, a decline of 1.2 percent. Results were weighed down by an unfavorable $2.76 per share impact tied to acquired in-process research and development and milestone expenses.
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues, a 14.0 percent increase reported. Skyrizi led the portfolio with $17.56 billion in sales, followed by Rinvoq at $8.30 billion, while Humira contributed $4.54 billion as the company continues its transition away from the former blockbuster.
The neuroscience portfolio posted $10.77 billion in full-year revenues, climbing 19.6 percent. Vraylar generated $3.62 billion, Botox Therapeutic reached $3.77 billion, and the combined migraine treatments Ubrelvy and Qulipta delivered $2.31 billion.
Oncology revenues rose more modestly, increasing 1.5 percent to $6.66 billion. Imbruvica and Venclexta contributed $2.87 billion and $2.79 billion, respectively, while Elahere added $690 million.
Aesthetics was the lone area of decline. The portfolio generated $4.86 billion in revenue, down 6.1 percent year over year. Botox Cosmetic produced $2.60 billion, while Juvederm delivered $993 million.
Fourth-quarter performance mirrored the full-year trend. AbbVie reported quarterly net revenues of $16.62 billion, up 10.0 percent reported. GAAP diluted EPS was $1.02, while adjusted diluted EPS reached $2.71, including a $0.71 per share unfavorable impact from acquired IPR&D and milestone expenses.
Looking ahead, AbbVie issued 2026 adjusted diluted EPS guidance of $14.37 to $14.57, excluding any potential impact from future acquired IPR&D and milestone charges.
